

Armando Tripodi

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7948115/armando-tripodi-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

189
papers

9,616
citations

47
h-index

95
g-index

198
ext. papers

11,146
ext. citations

6.2
avg. IF

6.74
L-index

#	Paper	IF	Citations
189	The coagulopathy of chronic liver disease. <i>New England Journal of Medicine</i> , 2011 , 365, 147-56	59.2	935
188	Hypercoagulability of COVID-19 patients in intensive care unit: A report of thromboelastography findings and other parameters of hemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1738-1742	15.4	787
187	Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. <i>Hepatology</i> , 2005 , 41, 553-8	11.2	506
186	D-dimer testing to determine the duration of anticoagulation therapy. <i>New England Journal of Medicine</i> , 2006 , 355, 1780-9	59.2	493
185	An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis. <i>Gastroenterology</i> , 2009 , 137, 2105-11	13.3	385
184	Thrombin generation in patients with cirrhosis: the role of platelets. <i>Hepatology</i> , 2006 , 44, 440-5	11.2	289
183	COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). <i>Blood Transfusion</i> , 2020 , 18, 167-169	3.6	168
182	Thrombin Generation Assay and Its Application in the Clinical Laboratory. <i>Clinical Chemistry</i> , 2016 , 62, 699-707	5.5	164
181	The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. <i>Hepatology</i> , 2007 , 46, 520-7	11.2	158
180	Abnormalities of hemostasis in chronic liver disease: reappraisal of their clinical significance and need for clinical and laboratory research. <i>Journal of Hepatology</i> , 2007 , 46, 727-33	13.4	147
179	A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. <i>Blood</i> , 2004 , 104, 3631-4	2.2	143
178	Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). <i>Thrombosis and Haemostasis</i> , 2011 , 106, 868-76	7	135
177	The coagulopathy of cirrhosis assessed by thromboelastometry and its correlation with conventional coagulation parameters. <i>Thrombosis Research</i> , 2009 , 124, 132-6	8.2	127
176	Thrombin generation assessed as endogenous thrombin potential in patients with hyper- or hypo-coagulability. <i>Haematologica</i> , 2003 , 88, 547-54	6.6	126
175	D-dimer testing in laboratory practice. <i>Clinical Chemistry</i> , 2011 , 57, 1256-62	5.5	125
174	Diagnosis, Development, and Treatment of Portal Vein Thrombosis in Patients With and Without Cirrhosis. <i>Gastroenterology</i> , 2019 , 156, 1582-1599.e1	13.3	121
173	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2014 , 61, 148-54	13.4	113

172	Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis. <i>Journal of Hepatology</i> , 2013 , 59, 265-70	13.4	113
171	Changing Concepts of Cirrhotic Coagulopathy. <i>American Journal of Gastroenterology</i> , 2017 , 112, 274-281	10.7	110
170	Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. <i>Thrombosis Research</i> , 2016 , 137, 178-183	8.2	105
169	Detection of the imbalance of procoagulant versus anticoagulant factors in cirrhosis by a simple laboratory method. <i>Hepatology</i> , 2010 , 52, 249-55	11.2	103
168	Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 31, 165-72	5.1	102
167	Laboratory Investigation of Thrombophilia. <i>Clinical Chemistry</i> , 2001 , 47, 1597-1606	5.5	98
166	Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. <i>British Journal of Haematology</i> , 2009 , 147, 77-82	4.5	91
165	The laboratory and the direct oral anticoagulants. <i>Blood</i> , 2013 , 121, 4032-5	2.2	86
164	Global hemostasis tests in patients with cirrhosis before and after prophylactic platelet transfusion. <i>Liver International</i> , 2013 , 33, 362-7	7.9	84
163	Circulating microparticles and risk of venous thromboembolism. <i>Thrombosis Research</i> , 2012 , 129, 591-7	8.2	75
162	Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. <i>Internal and Emergency Medicine</i> , 2012 , 7, 139-44	3.7	73
161	Antiphospholipid antibody ELISAs: survey on the performance of clinical laboratories assessed by using lyophilized affinity-purified IgG with anticardiolipin and anti-beta2-Glycoprotein I activity. <i>Thrombosis Research</i> , 2007 , 120, 127-33	8.2	67
160	Laboratory control of oral anticoagulant treatment by the INR system in patients with the antiphospholipid syndrome and lupus anticoagulant. Results of a collaborative study involving nine commercial thromboplastins. <i>British Journal of Haematology</i> , 2001 , 115, 672-8	4.5	67
159	Hypercoagulability in splenectomized thalassaemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. <i>Haematologica</i> , 2009 , 94, 1520-7	6.6	66
158	Lupus anticoagulant (LA) testing: performance of clinical laboratories assessed by a national survey using lyophilized affinity-purified immunoglobulin with LA activity. <i>Clinical Chemistry</i> , 2003 , 49, 1608-14	5.5	61
157	Laboratory Diagnosis of Lupus Anticoagulants for Patients on Oral Anticoagulant Treatment. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 583-586	7	59
156	Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 2828-2839	15.4	57
155	Unbalanced oxidative status in idiopathic sudden sensorineural hearing loss. <i>European Archives of Oto-Rhino-Laryngology</i> , 2012 , 269, 449-53	3.5	56

154	The endogenous thrombin potential and the risk of venous thromboembolism. <i>Thrombosis Research</i> , 2007 , 121, 353-9	8.2	56
153	Are Capillary Whole Blood Coagulation Monitors Suitable for the Control of Oral Anticoagulant Treatment by the International Normalized Ratio?. <i>Thrombosis and Haemostasis</i> , 1993 , 70, 0921-0924	7	55
152	Normal thrombin generation in neonates in spite of prolonged conventional coagulation tests. <i>Haematologica</i> , 2008 , 93, 1256-9	6.6	53
151	The laboratory and the new oral anticoagulants. <i>Clinical Chemistry</i> , 2013 , 59, 353-62	5.5	52
150	Increased thrombin generation in inflammatory bowel diseases. <i>Thrombosis Research</i> , 2010 , 125, 278-82	8.2	52
149	Laboratory testing for lupus anticoagulants: a review of issues affecting results. <i>Clinical Chemistry</i> , 2007 , 53, 1629-35	5.5	52
148	International Collaborative Study for the Calibration of a Proposed Reference Preparation for Thromboplastin, Human Recombinant, Plain. <i>Thrombosis and Haemostasis</i> , 1998 , 79, 439-443	7	52
147	Silica clotting time (SCT) as a screening and confirmatory test for detection of the lupus anticoagulants. <i>Thrombosis Research</i> , 1992 , 67, 355-65	8.2	52
146	Second international collaborative study evaluating performance characteristics of methods measuring the von Willebrand factor cleaving protease (ADAMTS-13). <i>Journal of Thrombosis and Haemostasis</i> , 2008 , 6, 1534-41	15.4	51
145	Laboratory Screening of Inherited Thrombotic Syndromes. <i>Thrombosis and Haemostasis</i> , 1987 , 57, 247-251	7	51
144	Multicenter Study of Homocysteine Measurement [Performance Characteristics of Different Methods, Influence of Standards on Interlaboratory Agreement of Results. <i>Thrombosis and Haemostasis</i> , 2001 , 85, 291-295	7	47
143	Harmful and Beneficial Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis. <i>Clinical Gastroenterology and Hepatology</i> , 2018 , 16, 1146-1152.e4	6.9	46
142	Abnormalities of hemostasis and bleeding in chronic liver disease: the paradigm is challenged. <i>Internal and Emergency Medicine</i> , 2010 , 5, 7-12	3.7	43
141	Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. <i>Digestive and Liver Disease</i> , 2016 , 48, 455-467	3.3	41
140	Hemostasis abnormalities in cirrhosis. <i>Current Opinion in Hematology</i> , 2015 , 22, 406-12	3.3	41
139	Screening for the FV: Q506 Mutation [Evaluation of Thirteen Plasma-based Methods for their Diagnostic Efficacy in Comparison with DNA Analysis. <i>Thrombosis and Haemostasis</i> , 1997 , 77, 436-439	7	41
138	Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. <i>Journal of Hepatology</i> , 2020 , 72, 85-94	13.4	39
137	Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 1569-1575	15.4	38

136	Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations [A Cause for Concern. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 690-691	7	37
135	Hemostatic defects in liver and renal dysfunction. <i>Hematology American Society of Hematology Education Program</i> , 2012 , 2012, 168-173	3.1	37
134	Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis. <i>Liver International</i> , 2016 , 36, 1322-30	7.9	36
133	Lupus anticoagulants and their relationship with the inhibitors against coagulation factor VIII: considerations on the differentiation between the 2 circulating anticoagulants. <i>Clinical Chemistry</i> , 2005 , 51, 1883-5	5.5	36
132	Liver Disease and Hemostatic (Dys)function. <i>Seminars in Thrombosis and Hemostasis</i> , 2015 , 41, 462-7	5.3	35
131	Tests of coagulation in liver disease. <i>Clinics in Liver Disease</i> , 2009 , 13, 55-61	4.6	35
130	Near-patient testing devices to monitor oral anticoagulant therapy. <i>British Journal of Haematology</i> , 2001 , 113, 847-52	4.5	35
129	Position Paper on laboratory testing for patients on direct oral anticoagulants. A Consensus Document from the Siset, FCSA, SIBioC and SIPMeL. <i>Blood Transfusion</i> , 2018 , 16, 462-470	3.6	35
128	Assessment of the Influence of Citrate Concentration on the International Normalized Ratio (INR) Determined with Twelve Reagent-instrument Combinations. <i>Thrombosis and Haemostasis</i> , 1998 , 80, 258-262	7.2	34
127	A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, e309-10	9.4	33
126	A review of the clinical and diagnostic utility of laboratory tests for the detection of congenital thrombophilia. <i>Seminars in Thrombosis and Hemostasis</i> , 2005 , 31, 25-32	5.3	33
125	Reliability of international normalised ratios from two point of care test systems: comparison with conventional methods. <i>BMJ, The</i> , 2003 , 327, 30	5.9	32
124	How the direct oral anticoagulant apixaban affects thrombin generation parameters. <i>Thrombosis Research</i> , 2015 , 135, 1186-90	8.2	31
123	D-dimer testing for suspected venous thromboembolism in the emergency department. Consensus document of AcEMC, CISMEL, SIBioC, and SIMeL. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014 , 52, 621-8	5.9	30
122	Anticoagulant treatment with rivaroxaban in severe protein S deficiency. <i>Pediatrics</i> , 2013 , 132, e1435-9	7.4	30
121	Laboratory testing for lupus anticoagulants: diagnostic criteria and use of screening, mixing, and confirmatory studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 373-9	5.3	28
120	A National Field Study of Quality Assessment of CoaguChek Point-of-Care Testing Prothrombin Time Monitors. <i>American Journal of Clinical Pathology</i> , 2006 , 126, 756-761	1.9	28
119	Extracellular vesicle-driven information mediates the long-term effects of particulate matter exposure on coagulation and inflammation pathways. <i>Toxicology Letters</i> , 2016 , 259, 143-150	4.4	28

118	To mix or not to mix in lupus anticoagulant testing? That is the question. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 385-9	5.3	27
117	Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study. <i>Haematologica</i> , 2008 , 93, 900-7	6.6	27
116	Levels of coagulation factors and venous thromboembolism. <i>Haematologica</i> , 2003 , 88, 705-11	6.6	27
115	The coagulopathy of chronic liver disease: is there a causal relationship with bleeding? No. <i>European Journal of Internal Medicine</i> , 2010 , 21, 65-9	3.9	26
114	Hyperprothrombinemia may result in acquired activated protein C resistance. <i>Blood</i> , 2000 , 96, 3295-3296	6.2	26
113	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago. <i>Internal and Emergency Medicine</i> , 2017 , 12, 1109-1119	3.7	25
112	Detection of procoagulant imbalance. Modified endogenous thrombin potential with results expressed as ratio of values with-to-without thrombomodulin. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 830-836	7	25
111	A new chromogenic assay (HemosIL ThromboPath) is sensitive to major prothrombotic risk factors affecting the protein C pathway. Results of a multicenter study. <i>Thrombosis Research</i> , 2009 , 124, 137-43	8.2	25
110	Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. <i>Journal of Hepatology</i> , 2009 , 51, 288-95	13.4	25
109	Determination of the International Sensitivity Index of a New Near-Patient Testing Device to Monitor Oral Anticoagulant Therapy. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 855-858	7	24
108	Hemostatic alterations in COVID-19. <i>Haematologica</i> , 2021 , 106, 1472-1475	6.6	24
107	Hemostasis in Acute and Chronic Liver Disease. <i>Seminars in Liver Disease</i> , 2017 , 37, 28-32	7.3	22
106	Laboratory monitoring of anticoagulation: where do we stand?. <i>Seminars in Thrombosis and Hemostasis</i> , 2009 , 35, 34-41	5.3	22
105	European Concerted Action on Anticoagulation. Use of Plasma Samples to Derive International Sensitivity Index for Whole-Blood Prothrombin Time Monitors. <i>Clinical Chemistry</i> , 2002 , 48, 255-260	5.5	22
104	Calibration of Local Systems with Lyophilized Calibrant Plasmas Improves the Interlaboratory Variability of the INR in the Italian External Quality Assessment Scheme. <i>Thrombosis and Haemostasis</i> , 1999 , 82, 1621-1626	7	22
103	Liver disease, coagulopathies and transfusion therapy. <i>Blood Transfusion</i> , 2013 , 11, 32-6	3.6	22
102	Global coagulation in myeloproliferative neoplasms. <i>Annals of Hematology</i> , 2013 , 92, 1633-9	3	21
101	How to evaluate the influence of blood collection systems on the international sensitivity index. Protocol applied to two new evacuated tubes and eight coagulometer/thromboplastin combinations. <i>Thrombosis Research</i> , 2002 , 108, 85-9	8.2	20

100	Hypercoagulability in patients with Cushing disease detected by thrombin generation assay is associated with increased levels of neutrophil extracellular trap-related factors. <i>Endocrine</i> , 2017 , 56, 298-307	4	19
99	Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL1). <i>Clinical Chemistry and Laboratory Medicine</i> , 2012 , 50, 2137-40	5.9	19
98	Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban. <i>Haematologica</i> , 2018 , 103, e315-e317	6.6	18
97	European concerted action on anticoagulation. Quality assessment of the CoaguChek Mini and TAS PT-NC point-of-care whole-blood prothrombin time monitors. <i>Clinical Chemistry</i> , 2004 , 50, 537-44	5.5	18
96	The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1116-1122	15.4	18
95	Coagulation parameters in patients with cirrhosis and portal vein thrombosis treated sequentially with low molecular weight heparin and vitamin K antagonists. <i>Digestive and Liver Disease</i> , 2016 , 48, 1208-13	3.3	18
94	The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures. <i>Internal and Emergency Medicine</i> , 2018 , 13, 1029-1036	3.7	17
93	Advances in the Treatment of Hemophilia: Implications for Laboratory Testing. <i>Clinical Chemistry</i> , 2019 , 65, 254-262	5.5	17
92	Laboratory diagnostic outcome applying detection criteria recommended by the Scientific and Standardization Committee of the ISTH on Lupus Anticoagulant. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 46-52	7	16
91	Standardization of the endogenous thrombin potential measurement: how to minimize the effect of residual platelets in stored plasma. <i>British Journal of Haematology</i> , 2004 , 124, 355-7	4.5	16
90	Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test?. <i>Thrombosis and Haemostasis</i> , 2011 , 105, 735-6	7	15
89	Evaluation of coagulation during treatment with directly acting antivirals in patients with hepatitis C virus related cirrhosis. <i>Liver International</i> , 2017 , 37, 1295-1303	7.9	14
88	How to report results of prothrombin and activated partial thromboplastin times. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016 , 54, 215-22	5.9	14
87	Procoagulant imbalance in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2017 , 66, 248-250	13.4	14
86	Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism. <i>Journal of Thrombosis and Thrombolysis</i> , 2010 , 30, 215-9	5.1	14
85	Laboratory Diagnosis of Lupus Anticoagulants. <i>Thrombosis and Haemostasis</i> , 2002 , 87, 854-858	7	14
84	Quality assurance program for whole blood prothrombin time-international normalized ratio point-of-care monitors used for patient self-testing to control oral anticoagulation. <i>Thrombosis Research</i> , 2004 , 113, 35-40	8.2	14
83	Standardization of the APC Resistance Test. Effects of Normalization of Results by Means of Pooled Normal Plasma. <i>Thrombosis and Haemostasis</i> , 1998 , 79, 564-566	7	14

82	Recombinant Tissue Factor as Substitute for Conventional Thromboplastin in the Prothrombin Time Test. <i>Thrombosis and Haemostasis</i> , 1992 , 67, 042-045	7	14
81	How the direct oral anticoagulant apixaban affects hemostatic parameters. Results of a multicenter multiplatform study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2015 , 53, 265-73	5.9	13
80	European Concerted Action on Anticoagulation. Evaluation of a Method for International Sensitivity Index Calibration of Two Point-of-Care Prothrombin Time (PT) Monitoring Systems (CoaguChek Mini and TAS PT-NC) with Fresh Plasmas Based on Whole-Blood Equivalent PT. <i>Clinical Chemistry</i> , 2002 , 48, 1672-1680	5.5	13
79	Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 583-6	7	13
78	Critical laboratory values in hemostasis: toward consensus. <i>Annals of Medicine</i> , 2017 , 49, 455-461	1.5	12
77	Statins decrease thrombin generation in patients with hypercholesterolemia. <i>European Journal of Internal Medicine</i> , 2014 , 25, 449-51	3.9	12
76	The history of phenotypic testing in thrombosis and hemostasis. <i>Seminars in Thrombosis and Hemostasis</i> , 2008 , 34, 585-92	5.3	12
75	Performance of clinical laboratories for DNA analyses to detect thrombophilia mutations. <i>Clinical Chemistry</i> , 2005 , 51, 1310-1	5.5	12
74	Thrombin generation and other coagulation parameters in a patient with homozygous congenital protein S deficiency on treatment with rivaroxaban. <i>International Journal of Hematology</i> , 2016 , 103, 165-72	7.2	11
73	Laboratory tests and the new oral anticoagulants. <i>Thrombosis Research</i> , 2012 , 130 Suppl 1, S95-7	8.2	11
72	Problems and solutions for testing hemostasis assays while patients are on anticoagulants. <i>Seminars in Thrombosis and Hemostasis</i> , 2012 , 38, 586-92	5.3	11
71	How to implement the modified international normalized ratio for cirrhosis (INR(liver)) for model for end-stage liver disease calculation. <i>Hepatology</i> , 2008 , 47, 1423-4; author reply 1424	11.2	11
70	Thromboelastographic profiles of healthy very low birthweight infants serially during their first month. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2020 , 105, 412-418	4.7	11
69	Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and Siset. <i>Haemophilia</i> , 2020 , 26, 937-945	3.3	10
68	International Sensitivity Index Calibration of the Near-Patient Testing Prothrombin Time Monitor, ProTime. <i>American Journal of Clinical Pathology</i> , 2003 , 119, 241-245	1.9	9
67	Issues concerning the laboratory investigation of inherited thrombophilia. <i>Molecular Diagnosis and Therapy</i> , 2005 , 9, 181-6		9
66	Factor VIII activity as measured by an amidolytic assay compared with a one-stage clotting assay. <i>American Journal of Clinical Pathology</i> , 1986 , 86, 341-4	1.9	9
65	The intra-assay reproducibility of thromboelastography in very low birth weight infants. <i>Early Human Development</i> , 2018 , 127, 48-52	2.2	9

64	Nontransfusal approach to increased platelet count in patients with cirrhosis and thrombocytopenia. <i>Hepatology</i> , 2013 , 58, 1177-80	11.2	8
63	Standardization of lupus anticoagulant. Feasibility study of a calibration model to minimize between-method variability. <i>Thrombosis Research</i> , 2011 , 127, 589-94	8.2	8
62	Pro-coagulant imbalance in patients with chronic liver disease. <i>Journal of Hepatology</i> , 2010 , 53, 586-7	13.4	8
61	Thrombin generation in patients with idiopathic sudden sensorineural hearing loss. <i>Thrombosis Research</i> , 2014 , 133, 1130-4	8.2	7
60	Results expression for tests used to measure the anticoagulant effect of new oral anticoagulants. <i>Thrombosis Journal</i> , 2013 , 11, 9	5.6	7
59	Haemostasis Abnormalities in Chronic Liver Failure 2011 , 289-303		7
58	European Concerted Action on Anticoagulation. <i>American Journal of Clinical Pathology</i> , 2003 , 119, 232-240		7
57	Prothrombin time international normalized ratio monitoring by self-testing. <i>Current Opinion in Hematology</i> , 2004 , 11, 141-5	3.3	7
56	Standardization of activated protein C resistance testing: effect of residual platelets in frozen plasmas assessed by commercial and home-made methods. <i>British Journal of Haematology</i> , 2003 , 120, 825-8	4.5	6
55	Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 1372-1378	15.4	6
54	Body mass index reduction improves the baseline procoagulant imbalance of obese subjects. <i>Journal of Thrombosis and Thrombolysis</i> , 2019 , 48, 52-60	5.1	5
53	Unexpected, isolated activated partial thromboplastin time prolongation: A practical mini-review. <i>European Journal of Haematology</i> , 2020 , 104, 519-525	3.8	5
52	Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis. <i>Liver International</i> , 2019 , 39, 2309-2316	7.9	5
51	Lupus Anticoagulant Testing: Activated Partial Thromboplastin Time (APTT) and Silica Clotting Time (SCT). <i>Methods in Molecular Biology</i> , 2017 , 1646, 177-183	1.4	5
50	Reply to: Endogenous heparinoids contribute to coagulopathy in patients with liver disease. <i>Journal of Hepatology</i> , 2008 , 48, 372-373	13.4	5
49	Laboratory diagnosis of thrombophilic states: where do we stand?. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2002 , 32, 245-8		5
48	Alpha(2)-macroglobulin levels are high in adult patients with congenital antithrombin deficiency. <i>Thrombosis Research</i> , 2000 , 98, 117-22	8.2	5
47	Procoagulant imbalance in preterm neonates detected by thrombin generation procedures. <i>Thrombosis Research</i> , 2020 , 185, 96-101	8.2	5

46	Relatively poor performance of clinical laboratories for DNA analyses in the detection of two thrombophilic mutations--a cause for concern. <i>Thrombosis and Haemostasis</i> , 2002 , 88, 690-1	7	5
45	Periprocedural management of rivaroxaban-treated patients. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 685-91	4	4
44	Emicizumab, the factor VIII mimetic bi-specific monoclonal antibody and its measurement in plasma. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 59, 365-371	5.9	4
43	Thrombin generation assay for testing hemostatic effect of factor VIII concentrates in patients with hemophilia A and inhibitors: In vitro results from the PredicTGA study. <i>Thrombosis Research</i> , 2019 , 174, 84-87	8.2	4
42	Is placental blood a reliable source for the evaluation of neonatal hemostasis at birth?. <i>Transfusion</i> , 2020 , 60, 1069-1077	2.9	4
41	Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia. <i>Haematologica</i> , 2021 , 106, 3021-3024	6.6	4
40	Effect of different methods for outlier detection and rejection when calculating cut off values for diagnosis of lupus anticoagulants. <i>Thrombosis Research</i> , 2020 , 190, 20-25	8.2	3
39	Comments on: Laboratory tests for the management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants: proposals of the Working Group on Perioperative Haemostasis (GIHP). <i>Archives of Cardiovascular Diseases</i> , 2014 , 107, 345-6	2.7	3
38	Coagulation and fibrosis: A potential non-negligible target of statins in chronic hepatitis. <i>Journal of Hepatology</i> , 2015 , 63, 277-8	13.4	3
37	The validity of the INR system for patients with liver disease. <i>Journal of Thrombosis and Thrombolysis</i> , 2011 , 31, 209-10	5.1	3
36	Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2021 ,	15.4	3
35	Heparin induced thrombocytopenia: position paper from the Italian Society on Thrombosis and Haemostasis (SISSET). <i>Blood Transfusion</i> , 2021 , 19, 14-23	3.6	3
34	Position paper on the safety/efficacy profile of Direct Oral Anticoagulants in patients with Chronic Kidney Disease: Consensus document of Societ� Italiana di Nefrologia (SIN), Federazione Centri per la diagnosi della trombosi e la Sorveglianza delle terapie Antitrombotiche (FCSA) and Societ� Italiana per lo Studio dell'Emostasi e della Trombosi (SISSET). <i>Journal of Nephrology</i> , 2021 , 34, 31-38	4.8	3
33	Direct oral anticoagulants and cirrhosis: More evidence still needed for efficacy and safety in portal vein thrombosis. <i>Vascular Pharmacology</i> , 2019 , 113, 92-93	5.9	2
32	Laboratory tests during direct oral anticoagulant treatment. <i>Internal and Emergency Medicine</i> , 2014 , 9, 903-5	3.7	2
31	Interference of factor V Leiden on protein S activity: evaluation of a new prothrombin time-based assay. <i>Blood Coagulation and Fibrinolysis</i> , 2007 , 18, 543-6	1	2
30	Issues Concerning the Laboratory Investigation of Inherited Thrombophilia 2005 , 9, 181		2
29	Effect of emicizumab on global coagulation assays for plasma supplemented with apixaban or argatroban. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 413-419	5.1	2

28	Anti-TNF- α treatment Reduces the Baseline Procoagulant Imbalance of Patients With Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2021 , 27, 1901-1908	4.5	2
27	Impact of a commercially available DOAC absorbent on two integrated procedures for lupus anticoagulant detection. <i>Thrombosis Research</i> , 2021 , 204, 32-39	8.2	2
26	Hemostasis abnormalities in liver cirrhosis: myth or reality? 2008 , 118, 445-8		2
25	Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3117-3118	15.4	1
24	Responsiveness of the activated partial thromboplastin time and dilute thrombin time to argatroban: Results of an in vitro study. <i>International Journal of Laboratory Hematology</i> , 2020 , 42, e128-e131	2.5	1
23	Documento di consenso FCSA, SIMeL, SIBioC e CISMEL sul monitoraggio di laboratorio dei nuovi farmaci anticoagulanti orali. <i>Rivista Italiana Della Medicina Di Laboratorio</i> , 2013 , 9, 131-133	1.1	1
22	Management of special conditions in patients on vitamin K antagonists. <i>Internal and Emergency Medicine</i> , 2012 , 7, 407-13	3.7	1
21	Thrombin Generation in Severe Hemophiliacs with Different Clinical Phenotype.. <i>Blood</i> , 2006 , 108, 1000-1000	1.00	1
20	Rebuttal to letter "Is thromboprophylaxis with high-dose enoxaparin really necessary for COVID-19 patients? A new "prudent" randomised clinical trial". <i>Blood Transfusion</i> , 2020 , 18, 239-240	3.6	1
19	Usefulness of Thrombin Generation. <i>Hamostaseologie</i> , 2020 , 40, 509-514	1.9	1
18	Thrombin Generation in Preterm Newborns With Intestinal Failure-Associated Liver Disease. <i>Frontiers in Pediatrics</i> , 2020 , 8, 510	3.4	1
17	Relationship between thrombin generation parameters and prothrombin fragment 1+2 plasma levels. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, e248-e251	2.5	1
16	Diagnostic Challenges on the Laboratory Detection of Lupus Anticoagulant. <i>Biomedicines</i> , 2021 , 9,	4.8	1
15	No changes of parameters nor coagulation activation in healthy subjects vaccinated for SARS-Cov-2. <i>Thrombosis Update</i> , 2021 , 4, 100059	0.9	1
14	Letter to the Editor: Thromboelastography-Guided Blood Product Transfusion in Cirrhosis With Coagulopathy: Real Saving or Just Less Waste?. <i>Hepatology</i> , 2020 , 72, 1158-1159	11.2	0
13	Procoagulant Imbalance in Klinefelter Syndrome Assessed by Thrombin Generation Assay and Whole-Blood Thromboelastometry. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e1660-e1672	5.6	0
12	Pro-coagulant imbalance in patients with community acquired pneumonia assessed on admission and one month after hospital discharge. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021 , 59, 1699-1708	5.9	0
11	Response to Portal vein thrombosis after hepatitis C eradication with direct acting antiviral therapy. <i>Liver International</i> , 2018 , 38, 186	7.9	

